Does the media refer more to CRSP or WVE?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for WAVE Life Sciences. CRISPR Therapeutics' average media sentiment score of 1.29 beat WAVE Life Sciences' score of 0.32 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DNTH or WVE?

In the previous week, WAVE Life Sciences had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 6 mentions for WAVE Life Sciences and 3 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat WAVE Life Sciences' score of 0.32 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NNNN or WVE?

WAVE Life Sciences has a consensus price target of $27.25, suggesting a potential upside of 335.65%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 WAVE Life Sciences 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.87

Which has stronger earnings and valuation, NNNN or WVE?

Anbio Biotechnology has higher earnings, but lower revenue than WAVE Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 524.82 $6.40M N/A N/A WAVE Life Sciences $42.73M 28.16 -$204.38M -$1.06 N/A

Does the media prefer NNNN or WVE?

In the previous week, WAVE Life Sciences had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for WAVE Life Sciences and 3 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 0.67 beat WAVE Life Sciences' score of 0.32 indicating that Anbio Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is WVE or INDV more profitable?

Indivior has a net margin of 19.44% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -255.70% -56.76% -42.80% Indivior 19.44% -219.26% 29.40%

Does the media favor WVE or INDV?

In the previous week, WAVE Life Sciences had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for WAVE Life Sciences and 2 mentions for Indivior. Indivior's average media sentiment score of 0.82 beat WAVE Life Sciences' score of 0.32 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MANE or WVE?

MANE has higher earnings, but lower revenue than WAVE Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MANE N/A N/A N/A N/A N/A WAVE Life Sciences $42.73M 28.16 -$204.38M -$1.06 N/A

Is MANE or WVE more profitable?

MANE has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. MANE's return on equity of 0.00% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets MANE N/A N/A N/A WAVE Life Sciences -255.70% -56.76% -42.80%

Does the media prefer MANE or WVE?

In the previous week, MANE and MANE both had 6 articles in the media. MANE's average media sentiment score of 0.40 beat WAVE Life Sciences' score of 0.32 indicating that MANE is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MANE 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

WAVE Life Sciences (WVE) Competitors

$6.26 -0.33 (-4.94%)

Closing price 03:59 PM Eastern

Extended Trading

$6.26 0.00 (0.00%)

As of 04:13 PM Eastern

Compare

WVE vs. CRSP, DNTH, NNNN, INDV, and MANE

Should you buy WAVE Life Sciences stock or one of its competitors? MarketBeat compares WAVE Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with WAVE Life Sciences include CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), Anbio Biotechnology (NNNN), Indivior (INDV), and MANE (MANE). These companies are all part of the "pharmaceutical products" industry.

How does WAVE Life Sciences compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

CRISPR Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market.

WAVE Life Sciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,490.85	-$581.60M	-$6.22	N/A
WAVE Life Sciences	$42.73M	28.16	-$204.38M	-$1.06	N/A

WAVE Life Sciences has a net margin of -255.70% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CRISPR Therapeutics presently has a consensus target price of $65.47, indicating a potential upside of 20.67%. WAVE Life Sciences has a consensus target price of $27.25, indicating a potential upside of 335.65%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

In the previous week, CRISPR Therapeutics had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for WAVE Life Sciences. CRISPR Therapeutics' average media sentiment score of 1.29 beat WAVE Life Sciences' score of 0.32 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

WAVE Life Sciences beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and WAVE Life Sciences (NASDAQ:WVE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market.

Dianthus Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,393.66	-$162.34M	-$4.13	N/A
WAVE Life Sciences	$42.73M	28.16	-$204.38M	-$1.06	N/A

WAVE Life Sciences has a net margin of -255.70% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 31.91%. WAVE Life Sciences has a consensus target price of $27.25, indicating a potential upside of 335.65%. Given WAVE Life Sciences' higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, WAVE Life Sciences had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 6 mentions for WAVE Life Sciences and 3 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.01 beat WAVE Life Sciences' score of 0.32 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

WAVE Life Sciences beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and WAVE Life Sciences (NASDAQ:WVE) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

WAVE Life Sciences has a consensus price target of $27.25, suggesting a potential upside of 335.65%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Anbio Biotechnology has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Anbio Biotechnology's return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Anbio Biotechnology has higher earnings, but lower revenue than WAVE Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	524.82	$6.40M	N/A	N/A
WAVE Life Sciences	$42.73M	28.16	-$204.38M	-$1.06	N/A

In the previous week, WAVE Life Sciences had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for WAVE Life Sciences and 3 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 0.67 beat WAVE Life Sciences' score of 0.32 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anbio Biotechnology has a beta of 4.4, meaning that its share price is 340% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its share price is 233% less volatile than the broader market.

89.7% of WAVE Life Sciences shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Anbio Biotechnology and WAVE Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does WAVE Life Sciences compare to Indivior?

WAVE Life Sciences (NASDAQ:WVE) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

WAVE Life Sciences presently has a consensus target price of $27.25, suggesting a potential upside of 335.65%. Indivior has a consensus target price of $39.33, suggesting a potential upside of 12.66%. Given WAVE Life Sciences' higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	28.16	-$204.38M	-$1.06	N/A
Indivior	$1.24B	3.44	$210M	$1.95	17.90

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Indivior has a net margin of 19.44% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Indivior	19.44%	-219.26%	29.40%

WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 4 more articles in the media than Indivior. MarketBeat recorded 6 mentions for WAVE Life Sciences and 2 mentions for Indivior. Indivior's average media sentiment score of 0.82 beat WAVE Life Sciences' score of 0.32 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Indivior beats WAVE Life Sciences on 10 of the 17 factors compared between the two stocks.

How does WAVE Life Sciences compare to MANE?

MANE (NYSE:MANE) and WAVE Life Sciences (NASDAQ:WVE) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

In the previous week, MANE and MANE both had 6 articles in the media. MANE's average media sentiment score of 0.40 beat WAVE Life Sciences' score of 0.32 indicating that MANE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MANE has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. MANE's return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

MANE presently has a consensus price target of $100.00, suggesting a potential downside of 1.92%. WAVE Life Sciences has a consensus price target of $27.25, suggesting a potential upside of 335.65%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

89.7% of WAVE Life Sciences shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MANE has higher earnings, but lower revenue than WAVE Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
WAVE Life Sciences	$42.73M	28.16	-$204.38M	-$1.06	N/A

Summary

WAVE Life Sciences beats MANE on 6 of the 10 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.20B	$3.32B	$6.31B	$12.61B
Dividend Yield	N/A	2.28%	2.68%	5.22%
P/E Ratio	-5.90	18.10	21.13	26.69
Price / Sales	28.16	327.47	546.80	115.09
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	2.02	6.85	9.95	6.90
Net Income	-$204.38M	$24.15M	$3.56B	$336.84M
7 Day Performance	-1.96%	2.03%	2.15%	4.24%
1 Month Performance	N/A	N/A	N/A	-0.07%
1 Year Performance	2.88%	63.17%	36.47%	40.32%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	2.7348 of 5 stars	$6.26 -4.9%	$27.25 +335.7%	+8.2%	$1.20B	$42.73M	N/A	240
CRSP CRISPR Therapeutics	2.4709 of 5 stars	$50.36 +0.9%	$65.47 +30.0%	+55.6%	$4.86B	$3.51M	N/A	460	Positive News
DNTH Dianthus Therapeutics	2.6707 of 5 stars	$86.48 -3.5%	$117.82 +36.2%	+433.9%	$4.73B	$2.04M	N/A	80
NNNN Anbio Biotechnology	0.579 of 5 stars	$32.52 +7.5%	N/A	N/A	$4.68B	$8.65M	N/A	27	News Coverage Short Interest Increase
INDV Indivior	3.1672 of 5 stars	$37.53 +0.2%	$39.33 +4.8%	+183.2%	$4.58B	$1.29B	19.25	1,051

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. CRSP, DNTH, NNNN, INDV, and MANE

How does WAVE Life Sciences compare to CRISPR Therapeutics?

Summary

How does WAVE Life Sciences compare to Dianthus Therapeutics?

Summary

How does WAVE Life Sciences compare to Anbio Biotechnology?

Summary

How does WAVE Life Sciences compare to Indivior?

Summary

How does WAVE Life Sciences compare to MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. CRSP, DNTH, NNNN, INDV, and MANE

How does WAVE Life Sciences compare to CRISPR Therapeutics?

Which has more volatility and risk, CRSP or WVE?

Which has stronger earnings and valuation, CRSP or WVE?

Is CRSP or WVE more profitable?

Do insiders & institutionals have more ownership in CRSP or WVE?

Do analysts recommend CRSP or WVE?

Does the media refer more to CRSP or WVE?

Summary

How does WAVE Life Sciences compare to Dianthus Therapeutics?

Which has more volatility & risk, DNTH or WVE?

Which has preferable valuation and earnings, DNTH or WVE?

Is DNTH or WVE more profitable?

Do analysts rate DNTH or WVE?

Do institutionals and insiders have more ownership in DNTH or WVE?

Does the media refer more to DNTH or WVE?

Summary

How does WAVE Life Sciences compare to Anbio Biotechnology?

Do analysts rate NNNN or WVE?

Is NNNN or WVE more profitable?

Which has stronger earnings and valuation, NNNN or WVE?

Does the media prefer NNNN or WVE?

Which has more volatility and risk, NNNN or WVE?

Do institutionals & insiders hold more shares of NNNN or WVE?

Summary

How does WAVE Life Sciences compare to Indivior?

Do analysts prefer WVE or INDV?

Which has better earnings & valuation, WVE or INDV?

Do insiders & institutionals believe in WVE or INDV?

Is WVE or INDV more profitable?

Which has more volatility & risk, WVE or INDV?

Does the media favor WVE or INDV?

Summary

How does WAVE Life Sciences compare to MANE?

Does the media prefer MANE or WVE?

Is MANE or WVE more profitable?

Do analysts recommend MANE or WVE?

Do institutionals and insiders believe in MANE or WVE?

Which has higher valuation & earnings, MANE or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools